AUTHORS
Veronica Ramirez, MD, Fanny Poissant2, Anne-Sophie Lemay, MD3, Alex Bourguignon, MD4, Benjamin Rioux-Massé, MD5, Nicolas Mercure-Corriveau, MD6, Jules M. Ross, MD7, Stephanie Forte, MD, MSc8
AFFILIATIONS
1 University of Montréal, Montréal, Quebec, Canada
2 University of Montréal, Montréal, Quebec, Canada
3 CHUM University of Montreal Hospital Center, Montréal, Quebec, Canada
4 CHUM University of Montreal Hospital Center, Montréal, Quebec, Canada
5 CHUM University of Montreal Hospital Center, Montréal, Quebec, Canada
6 CHUM University of Montreal Hospital Center, Montréal, Quebec, Canada
7 CHUM University of Montreal Hospital Center, Montréal, Quebec, Canada
8 CHUM University of Montreal Hospital Center, Montréal, Quebec, Canada
ABSTRACT
Background:
Red blood cell transfusion is a potentially life-saving therapy for sickle cell disease (SCD) complications. However, it carries significant risks, including alloimmunization, delayed hemolytic transfusion reactions (DHTR), and hyperhemolysis, making adherence to transfusion guidelines and safety practices essential. Despite this, few studies have systematically assessed adherence to SCD transfusion guidelines in clinical practice. We audited appropriateness and transfusion quality indicators of inpatient simple transfusions at a tertiary care centre.
Methods:
We retrospectively reviewed all inpatient simple transfusions to adults with SCD administered during five annual periods (January 1-April 30, 2022-2026). Non-bleeding transfusion events (TE) were classed as appropriate, potentially appropriate, and inappropriate according to predetermined criteria derived from international SCD guidelines. Evaluated quality indicators included: documentation of indications and consent, monitoring and incidence of DHTR and alloimmunization, and adherence to the institutional antigen-matching policy.
Results:
Overall, 174 red blood cell units were transfused to 66 patients; 18% (n=32) were administered for acute bleeding and were included only in safety assessments. Ninety-five non-bleeding TEs in 60 patients comprised the analytic cohort. Median age was 31 years (range 18-83); 65% had HbSS, 22% were enrolled in chronic transfusion programs and the median number of TEs per patient was one (range 1-7). Fifty-six TEs (59%) were classified as appropriate, 20 (21%) as potentially appropriate, and 19 (20%) as inappropriate. Among inappropriate TEs, indications included asymptomatic anemia (58%, n=11), uncomplicated vaso-occlusive crisis (21%, n=4), acute chest syndrome with hemoglobin >90 g/L (16%, n=3), and priapism (5%, n=1). Appropriate or potentially appropriate transfusions were more frequent with hematology consultation (82% vs. 73%), although this difference was not statistically significant (p=0.25). A non-significant trend towards decreased inappropriate TEs over time was observed (31% in 2022 vs. 11% in 2026, p=0.25).
Compliance with prophylactic antigen matching was 98% (170/174 units). Following transfusion, 82% of patients had laboratory follow-up sufficient to exclude DHTR, while 48% underwent antibody screening within 1-3 months. Two patients developed new alloantibodies (anti-Jka; anti-Jkb with anti-S), and no DHTR events were identified despite incomplete post-transfusion surveillance. Transfusion indication was documented in 84% of cases but accurately communicated on the blood bank requisition in only 39%. Informed consent was documented in only 24% of TEs (n=23), and SCD-specific transfusion risks were discussed in just seven cases.
Conclusions:
One in five inpatient transfusions for SCD were inappropriate according to current guidelines. This corresponds to approximately 11 potentially avoidable transfusion events annually at our institution, resulting in unnecessary exposure to transfusion-related risks and increased healthcare resource utilization. Most inappropriate transfusions were prescribed for asymptomatic anemia and uncomplicated vaso-occlusive crisis, highlighting a need for improved adherence to evidence-based transfusion practices. Gaps in systematic alloimmunization surveillance, documentation, and guideline adherence were identified. These findings provided an institutional baseline for targeted quality improvement initiatives, including multidisciplinary prescriber education, system-level interventions, and enhanced post-transfusion surveillance.
DISCLOSURES
Veronica Ramirez, MD: No relevant conflicts of interest to declare.